EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge

Ioannis Christofilis, Charikleia Triantopoulou, Spiros Delis iD

Diagnostics · 18.07.2025 · 15 (14) · 1810

DOI: 10.3390/diagnostics15141810 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 18.07.2025. Verfasst von Ioannis Christofilis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Radiology Department, Konstantopouleio Hospital, 142 33 Athens, Greece. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Assessing pancreatic ductal adenocarcinoma (PDAC) resectability after neoadjuvant therapy (NAT) remains a diagnostic challenge. Traditional computed tomography (CT) criteria often fail to distinguish viable tumor from fibrosis, necessitating a reassessment of imaging-based standards.

Methods

A comprehensive literature review was conducted using PubMed, focusing on prospective and retrospective studies over the past 25 years that evaluated the role of CT and complementary imaging modalities (MRI, PET-CT) in predicting resectability post-NAT in non-metastatic PDAC. Studies with small sample sizes or case reports were excluded.

Results

Across studies, conventional CT parameters—particularly >180° vascular encasement—showed a limited correlation with histologic invasion or surgical outcomes after NAT. Persistent vessel contact on CT often reflected fibrosis, rather than active tumor. Dynamic changes, such as regression in the tumor–vessel interface and vessel lumen restoration, correlated more accurately with R0 resection. Adjunct markers like CA 19-9 response and patient performance status further improved resectability prediction.

Conclusions

CT-based resectability assessment after NAT should transition from static morphologic criteria to response-based interpretation. Multidisciplinary evaluation integrating radiologic, biochemical, and clinical findings is essential to guide surgical decision-making and improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

computed tomographyimaging biomarkersneoadjuvant therapypancreatic cancerresectabilityvascular involvement

Autor:innen und Institutionen

  • Radiology Department, Konstantopouleio Hospital, 142 33 Athens, Greece.
  • HPB Unit, Konstantopouleio Hospital, 142 33 Athens, Greece.

ORCID-Profile: Spiros Delis

Zitieren

APA

Christofilis, I., Triantopoulou, C., & Delis, S. (2025). Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge. Diagnostics, 15(14), 1810. https://doi.org/10.3390/diagnostics15141810

Vancouver

Christofilis I, Triantopoulou C, Delis S. Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge. Diagnostics. 2025;15(14):1810. doi:10.3390/diagnostics15141810

BibTeX
@article{Christofilis2025,
  author = {Christofilis, Ioannis and Triantopoulou, Charikleia and Delis, Spiros},
  title = {Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge},
  journal = {Diagnostics},
  year = {2025},
  volume = {15},
  number = {14},
  pages = {1810},
  doi = {10.3390/diagnostics15141810}
}
Kostenlos starten →